{"id":"NCT01753310","sponsor":"Ipsen","briefTitle":"Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.","officialTitle":"A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-10","completion":"2015-01","firstPosted":"2012-12-20","resultsPosted":"2017-03-16","lastUpdate":"2019-08-07"},"enrollment":134,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cervical Dystonia"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dysport®","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the protocol is to evaluate the efficacy and safety of Dysport® using 2 mL dilution compared with placebo for the treatment of Cervical Dystonia.","primaryOutcome":{"measure":"Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4.","timeFrame":"4 weeks post-treatment","effectByArm":[{"arm":"Dysport®","deltaMin":42.5,"sd":10.4},{"arm":"Placebo","deltaMin":42.4,"sd":10.63}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":42,"countries":["United States"]},"refs":{"pmids":["33524060"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":88},"commonTop":["Muscular weakness","Neck Pain","Dysphagia","Headache","Sinusitis"]}}